Don’t distort enablement law, Amgen tells SCOTUS

Sanofi and Regeneron accused of wanting to change patent system | The US Supreme Court will decide whether a controversial court decision should stand.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Amgen v Sanofi: Scotus grapples with enablement

28 March 2023 As the US Supreme Court probed the key issue of enablement in Amgen v Sanofi, patent lawyers shared their views on the much-anticipated hearings.

Big Pharma

Deny Amgen’s ‘dangerous’ patent claims, Sanofi urges Supreme Court

7 February 2023 French pharma firm urges US court not to allow ‘monopoly’ over market | Enablement issue at centre of antibody patent case could have wide implications for pharma and life sciences industries.

Big Pharma

Amgen secures five-year ban on psoriasis drug copycat

20 April 2023 Court affirms decision that two Otezla patents are not invalid | Apremilast generics set for 2028 release.

More on this story

Americas

Amgen v Sanofi: Scotus grapples with enablement

28 March 2023 As the US Supreme Court probed the key issue of enablement in Amgen v Sanofi, patent lawyers shared their views on the much-anticipated hearings.

Big Pharma

Deny Amgen’s ‘dangerous’ patent claims, Sanofi urges Supreme Court

Big Pharma

Amgen secures five-year ban on psoriasis drug copycat

20 April 2023 Court affirms decision that two Otezla patents are not invalid | Apremilast generics set for 2028 release.

More on this story

Americas

Amgen v Sanofi: Scotus grapples with enablement

28 March 2023 As the US Supreme Court probed the key issue of enablement in Amgen v Sanofi, patent lawyers shared their views on the much-anticipated hearings.

Big Pharma

Deny Amgen’s ‘dangerous’ patent claims, Sanofi urges Supreme Court

Big Pharma

Amgen secures five-year ban on psoriasis drug copycat

20 April 2023 Court affirms decision that two Otezla patents are not invalid | Apremilast generics set for 2028 release.